1-(2-苯氧基乙基)-哌嗪 | 13484-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(2-苯氧基乙基)-哌嗪
• 中文别名: 1-(2-苯氧基乙基)哌嗪
• 英文名称: 1-[2-phenoxyethyl]piperazine
• 英文别名: 1-(2-Phenoxyethyl]piperazine；1-(2-phenoxyethyl)piperazine；4-(2-phenoxyethyl)piperazine；phenoxyethylpiperazine；1-(2-phenoxy-ethyl)-piperazine；1-(2-Phenoxy-aethyl)-piperazin
• CAS: 13484-37-2
• 化学式: C₁₂H₁₈N₂O
• mdl: MFCD00454314
• 分子量: 206.288
• InChiKey: PTJSLCXRMMGRLY-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R22,R20/21/22
• 海关编码：
  2933599090
• 危险类别：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1-(2-苯氧基乙基)-哌嗪 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 26.5h， 生成
  参考文献：
  名称：

  1-Phenoxyalkyl-4-[(N,N-disubstitutedamino)alkyl]piperazine derivatives as non-imidazole histamine H3-antagonists

  摘要：

  In this study, a series of 1-phenoxyalkyl-4-[(N,N-disubstitutedamino)alkyl]piperazine derivatives has been prepared and in vitro tested as H-3-receptor antagonists (electrically evoked contraction of the guinea pig jejunum). All compounds investigated show moderate in vitro affinities. The most potent antagonists in this series are the compounds 9b, 1b, 1f, and 1l, which exhibit, independently of the substituent at the end of -N- moiety, almost the same level of affinity (pA (2) = 7.18, pA (2) = 7.27, pA (2) = 7.13, pA (2) = 7.12, respectively). The histaminergic H-1 antagonism of the aforementioned four products was established on the isolated guinea pig ileum by conventional methods; the pA (2) values were compared with the potency of pyrilamine. None of them shows any H-1-antagonistic activity (pA (2) < 4; for pyrilamine pA (2) = 9.35).

  DOI：

  10.1007/s00044-012-0090-2
• 作为产物：
  描述：

  2-苯氧乙基溴 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 1-(2-苯氧基乙基)-哌嗪
  参考文献：
  名称：

  设计和合成新型有效的N，N-双（芳烷基）哌嗪衍生物作为多药抗性（MDR）逆转剂。

  摘要：

  合成和研究了一系列1,4-取代的芳基烷基哌嗪衍生物，目的是获得有效的P-gp依赖性多药耐药（MDR）反向剂。这些新化合物是在我们以前的芳胺酯衍生物具有高P-gp依赖性多药耐药性逆转活性的结构的基础上设计的。所有新化合物在耐阿霉素的红白血病K562细胞（K562 / DOX）的吡柔比星摄取测定中均具有活性。特别地，带有甲氧基芳族部分的化合物显示出相当高的逆转活性。通过评估它们对阿霉素的细胞毒性增强作用（逆向折叠，RF）以及P-gp介导的若丹明-123（Rhd 123）外排对K562 / DOX的抑制作用，进一步研究了最有效的化合物8、9、10和13。细胞系。所有药理学测定的结果表明，碱性哌嗪支架与芳基烷基残基的结合使我们获得了非常有趣的P-gp调节化合物。确定了两个持久的P-gp泵调制器（9和10）；他们能够在60分钟后显着抑制P-gp底物罗丹明123在耐药K562 / DOX细胞系上的流出

  DOI：

  10.1016/j.ejmech.2018.01.092

文献信息

• Potential hypnotics and anxiolytics in the 4H-s-triazolo[4,3-a]-1,4-benzodiazepine series: 8-Chloro-6-(2-chlorophenyl)-1-[4-(2-methoxyethyl)piperazino]-4H-s-triazolo[4,3-a]-1,4-benzodiazepine and some related compounds
  作者：Zdeněk Polívka、Miroslav Ryska、Jiří Holubek、Emil Svátek、Jan Metyš、Miroslav Protiva

  DOI：10.1135/cccc19832395

  日期：——

  1-Bromo derivatives XIIa and XIIb were prepared by bromination of 8-chloro-6-phenyl-4H-s-triazolo[4,3-a]-1,4-benzodiazepine (XIa) and its 6-(2-chlorophenyl) analogue XIb with bromine in chloroform in the presence of pyridine. Substitution reactions with 1-(2-methoxyethyl)piperazine (XIVb), 1-(3-methoxypropyl)piperazine (XVb), 1-(2-ethoxyethyl)piperazine (XVIb) and 1-(2-methylthioethyl)piperazine (XVIIb) afforded the title compound IIb and analogues IIa and IIIb-Vb. A substitution reaction of the bromo derivative XIIb with piperazine gave the 1-piperazino derivative VIIIb which was alkylated with 2-phenoxyethyl bromide and 2-phenylthioethyl bromide to give compounds VIb and VIIb. The title compound IIb has very high anticonvulsant and discoordinating activities in mice. The enlargement of the substituent R¹ (compounds IIIb-VIIb) results in a gradual decrease of the effects mentioned.

  1-溴衍生物XIIa和XIIb是通过在氯仿中存在吡啶的情况下，用溴对8-氯-6-苯基-4H-s-三唑并[4,3-a]-1,4-苯二氮杂环己烷（XIa）及其6-(2-氯苯基)类似物XIb进行溴化制备的。用1-(2-甲氧基乙基)哌嗪（XIVb）、1-(3-甲氧基丙基)哌嗪（XVb）、1-(2-乙氧基乙基)哌嗪（XVIb）和1-(2-甲硫基乙基)哌嗪（XVIIb）进行取代反应，得到了标题化合物IIb及其类似物IIa和IIIb-Vb。溴衍生物XIIb与哌嗪的取代反应得到了1-哌嗪基衍生物VIIIb，它与2-苯氧基乙溴和2-苯硫基乙溴烷基化，得到化合物VIb和VIIb。标题化合物IIb在小鼠中具有非常高的抗惊厥和失调活性。取代基R1的扩大（化合物IIIb-VIIb）导致上述效应逐渐减弱。
• Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)
  作者：Xiaoke Guo、Xianglei Ma、Qian Yang、Jing Xu、Lu Huang、Jianmin Jia、Jiaojiao Shan、Li Liu、Weilin Chen、Hongxi Chu、Jinlian Wei、Xiaojin Zhang、Haopeng Sun、Yiqun Tang、Qidong You

  DOI：10.1016/j.ejmech.2014.03.075

  日期：2014.6

  and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected

  Kv1.5钾通道是一种治疗房颤（AF）的有效且安全的治疗靶标，它是威胁人类的最常见心律不齐。本文中，通过从内部数据库中修改命中化合物7k，合成了48种衍生物，以通过全细胞膜片钳技术测定其Kv1.5抑制作用。选择了六种显示出比阳性化合物决奈达隆更好的效价的化合物用于其类药物性质的下一个评估。化合物8显示出平衡的溶解度和渗透性。它还显示出可接受的药效学特征，急性毒性非常低。考虑到所有这些数据，化合物8 可以作为开发用于治疗AF的新型治疗剂的有希望的先导。
• ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
  申请人：Herman Jean

  公开号：US20140088088A1

  公开（公告）日：2014-03-27

  The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 11 , and R 12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.

  本发明涉及式I、II、III或IV的化合物，和/或其药用可接受的加合物盐和/或其立体异构体和/或其溶剂化合物，式(I)、(II)、(III)和(IV)中R1、R2、R3、R4、R5、R6、R7、R8、R9、R11和R12如权利要求书中所定义或在发明说明书中详细描述的那样，以及使用所述化合物来治疗或预防增殖性疾病以及用于制造治疗或预防增殖性疾病的药物，特别是像白血病这样的癌症。本发明还涉及所述化合物的药物组合物以及使用所述药物组合物来治疗或预防增殖性疾病。本发明还涉及将所述化合物用作生物活性成分，更具体地用作治疗增殖性疾病和病理状况的药物，例如癌症如白血病等。
• Therapeutically Active Thiazolo-Pyrimidine Derivatives
  申请人：UCB Pharma S.A.

  公开号：US20140315885A1

  公开（公告）日：2014-10-23

  A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.

  一系列噻唑并[5,4-d]嘧啶衍生物的化学式(I)或其N-氧化物，或其药用可接受的盐或溶剂：(I) Q代表化学式(Qa)、(Qb)、(Qc)、(Qd)或(Qe)的基团，在治疗和/或预防各种人类疾病方面具有益处，包括炎症性、自身免疫和肿瘤性疾病；病毒性疾病；以及器官和细胞移植排斥反应。
• Synthesis and Preliminary Pharmacological Evaluation of 4′-Arylalkyl Analogues of Clozapine. IV. The Effects of Aromaticity and Isosteric Replacement
  作者：Ben Capuano、Ian T. Crosby、Edward J. Lloyd、Anna Podloucka、David A. Taylor

  DOI：10.1071/ch08307

  日期：——

  We report the synthesis and preliminary pharmacological activity of a new series of tricyclic analogues of clozapine as potential antipsychotic agents for the treatment of schizophrenia. These compounds were designed based on a revised structural model, and investigate the length and nature of a designated linker (alkyl and alkyloxy) and the nature of the introduced aryl group (aromatic and heteroaromatic). The chemistry and structural characterization of this series of 4′-arylalkyl(oxy) analogues of clozapine are described. Preliminary results on the pharmacological effects of the selected linkers and introduced aryl groups on affinity for dopamine D4 and serotonin 5-HT2A receptors are discussed. Psychosis-related animal behavioural data for promising compounds identified from the receptor binding screen are also presented.

  我们报告了一系列新的氯氮平三环类似物的合成和初步药理活性，它们是治疗精神分裂症的潜在抗精神病药物。这些化合物是根据修订后的结构模型设计的，研究了指定连接物（烷基和烷氧基）的长度和性质以及引入芳基的性质（芳香族和杂芳香族）。本文介绍了这一系列氯氮平的 4′-芳基烷氧基类似物的化学和结构特征。讨论了所选连接体和引入的芳基对多巴胺 D4 和血清素 5-HT2A 受体亲和力的药理作用的初步结果。此外，还介绍了从受体结合筛选中发现的有前景的化合物与精神错乱有关的动物行为数据。